IDH1 and acute myeloid leukemia: Analysis of 34 treatment naïve patients suggested efficacy in the frontline setting with an ORR of 42.4% and a median OS of 12.6 months, leading to FDA approval for ivosidenib monotherapy for both relapsed/refractory as well as newly diagnosed, older chemotherapy-ineligible patients with IDH1-mutated AML.